863288-34-0
CJC-1295 (no DAC)
Tetra-substituted GHRH(1-29) analogue without the drug affinity complex. Short-acting.
Typical release99.0%
From
£42.00
In stock
Growth Factor & SecretagogueMost ordered
Ipamorelin
NNC 26-0161
Selective ghrelin receptor agonist pentapeptide with minimal cross-activity.
Total, ex VAT
£34.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 170851-70-4
- Molecular formula
- C38H49N9O5
- Average mass
- 711.86 g/mol
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Residues
- 5
- Class
- Ghrelin receptor (GHS-R1a) agonist
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Growth hormone secretagogue receptor 1a (GHS-R1a)
Overview
About Ipamorelin
Ipamorelin is a five-residue synthetic secretagogue notable for its selectivity. Earlier compounds in the class produced measurable cortisol and prolactin release alongside growth hormone; ipamorelin was designed to avoid that, and its selectivity is the reason it is used as a clean GHS-R1a tool rather than as a general secretagogue.
It contains unnatural residues — aminoisobutyric acid at the N-terminus, D-2-naphthylalanine and D-phenylalanine — and is C-terminally amidated. Those modifications make it protease-resistant and are all confirmed by mass on the certificate.
In short
- Five residues with Aib, D-2-Nal and D-Phe; C-terminally amidated
- Selective for GHS-R1a without the cortisol and prolactin release of earlier secretagogues
- Used as a clean pharmacological tool at the ghrelin receptor
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Receptor selectivity
The compound's value is its clean profile — effects observed can be attributed to GHS-R1a rather than to off-target endocrine activity.
Secretagogue combination studies
Paired with a GHRH analogue to study how the two secretagogue pathways interact.
Gastrointestinal motility
GHS-R1a expression in the gut makes the compound relevant to motility work independent of the somatotropic axis.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of Ipamorelin and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Selectivity characterisation
The founding description of ipamorelin as a growth hormone releasing peptide without ACTH or cortisol-releasing activity.
Raun et al., European Journal of Endocrinology, 1998
Ghrelin receptor pharmacology
Broader characterisation of GHS-R1a and the structural basis of agonist selectivity.
Reviewed in Müller et al., Molecular Metabolism, 2015
Questions
Ipamorelin — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Why is selectivity important?
- Earlier secretagogues such as GHRP-6 raise cortisol and prolactin as well as growth hormone, which confounds interpretation. Ipamorelin does not, so an observed effect can be attributed to GHS-R1a.
- Does it contain unnatural amino acids?
- Yes — Aib, D-2-naphthylalanine and D-phenylalanine, plus C-terminal amidation. All are confirmed by mass on the certificate.
- What is the solution shelf life?
- 28 days at 2–8 °C.
Same class
Others in Growth Factor & Secretagogue
86168-78-7
Sermorelin
The native GHRH(1-29) fragment, unmodified. The reference sequence for GHRH analogue work.
Typical release98.8%From
£52.00
In stock
218949-48-5
Tesamorelin
Full-length GHRH(1-44) with an N-terminal hexenoyl group for protease resistance.
Typical release98.6%From
£114.00
In stock
87616-84-0
GHRP-6
First-generation hexapeptide secretagogue at GHS-R1a, with characteristic off-target endocrine activity.
Typical release99.0%From
£29.00
In stock
Important
Ipamorelin is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.